Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obecabtagene autoleucel – obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia (r/r B-ALL)
08. November 2024 16:23 ET
|
Autolus Therapeutics plc
Autolus Therapeutics Announces FDA Approval of AUCATZYL® (obe-cel) for adults with relapsed/refractory B-cell acute lymphoblastic leukemia
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024 in One Oral Presentation and Three Poster Presentations
05. November 2024 09:00 ET
|
Autolus Therapeutics plc
Autolus Therapeutics to Present Clinical Data Updates at the American Society of Hematology (ASH) Annual Meeting 2024
FDA Grants Regenerative Medicine Advanced Therapy (RMAT) designation to Autolus’ CAR T cell therapy, obe-cel, for the treatment of adult B-ALL
25. April 2022 07:01 ET
|
Autolus Therapeutics plc
LONDON, April 25, 2022 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics announces publication of obe-cel (AUTO1) Phase 1 ALLCAR19 data in adults with relapsed/ refractory B-ALL in Journal of Clinical Oncology
01. September 2021 07:00 ET
|
Autolus Therapeutics plc
LONDON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics Announces Conference Call to Review Clinical Data for Programmed T Cell Therapy Pipeline Presented at the 2019 ASH Annual Meeting
05. Dezember 2019 16:30 ET
|
Autolus Therapeutics plc
LONDON, Dec. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL) announced today that management will host a conference call and webcast on Monday, December 9, 2019 at 8:30 am ET /...
Autolus Therapeutics Reports Third Quarter 2019 Financial Results and Operational Progress
07. November 2019 07:06 ET
|
Autolus Therapeutics plc
LONDON, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Present New Data on Its Advanced Programmed T Cell Therapies at the 61st ASH Annual Meeting
06. November 2019 09:24 ET
|
Autolus Therapeutics plc
LONDON, Nov. 06, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment...
Autolus Therapeutics to Present Preclinical Data on AUT06NG at the SITC Annual Meeting
05. November 2019 09:35 ET
|
Autolus Therapeutics plc
LONDON, Nov. 05, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies for the treatment...
Autolus Therapeutics to Report Second Quarter 2019 Financial Results and Host Conference Call on August 8
02. August 2019 09:06 ET
|
Autolus Therapeutics plc
LONDON, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...
Autolus Therapeutics to Participate in Upcoming Investor Conferences in June
28. Mai 2019 16:55 ET
|
Autolus Therapeutics plc
LONDON, May 28, 2019 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced...